Drug Profile
Research programme: paracrine gene therapy - Renova
Alternative Names: AAV8.UCn2; Adeno-associated virus 8 vector encoding urocortin 2 - Renova Therapeutics; RT-110; RT-200; RT-210; RT-220; RT-230; RT-300; Urocortin-2 gene therapy - RenovaLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator University of California, San Diego
- Developer Renova Therapeutics
- Class Antihyperglycaemics; Cardiovascular therapies; Gene therapies; Hepatoprotectants; Obesity therapies
- Mechanism of Action Adenylate cyclase stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure; Non-alcoholic fatty liver disease; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (IV, Injection)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Heart-failure in USA (IV)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Heart-failure in USA (Intracoronary)